EULAR 2018 Review
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Real-world evidence: patterns of use with JAK inhibitors<br />
Chastek, et al. reported real-world patterns of use in biologic-naïve and biologicexperienced<br />
patients with RA who were newly prescribed a JAKi. In this retrospective<br />
analysis of 1059 patients (80.2% biologic-experienced), 72.4% of patients were not<br />
persistent for the 1-year following initiation of a JAKi, and 39.1% were not persistent<br />
beyond 90 days. For non-persistent patients, 42% interrupted JAKi treatment and<br />
restarted, 30% switched to a bDMARD and 28% discontinued. More biologic-naïve than<br />
biologic-experienced patients neither initiated a bDMARD nor restarted a JAKi after<br />
interruption (44.2% versus 23.3%, respectively; P
Change language